Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer’s Disease After 12 Weeks of Subcutaneous Treatment (P3-13.012)

Neurology 2026

View at publisher
Authors: Susan Alford, Peter Johannsen, Marie A. Bentsen, Dylan Belmont-Rausch, Lisbeth Carstensen, Rose Jeppesen, Gabriel Martino, Martí Jiménez Mausbach, Lotte Knudsen
DOI: 10.1212/wnl.0000000000216104
Cited by: 1

Abstract

To measure the concentration of semaglutide in the cerebrospinal fluid (CSF) of patients with early Alzheimer’s disease (AD) after 12 weeks’ treatment.

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Diabetes Treatment and Management Alzheimer's disease research and treatments

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
11_Supplement_1
Publication date
9 June 2026
Language
EN